成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

百奧邁科 Biomics
百奧邁科(Biomics)生物技術(shù)有限公司，是由國家“千人計劃”專家朱遠(yuǎn)源博士率領(lǐng)的海歸科研、管理團(tuán)隊于2006年在南通經(jīng)濟(jì)技術(shù)開發(fā)區(qū)創(chuàng)立，注冊資本1212萬美元，總投資2500萬美元，致力于第三代制藥——小核酸藥物研發(fā)與產(chǎn)業(yè)化。

　　百奧邁科由海歸高層次人才領(lǐng)軍研發(fā)、管理，目前擁有海歸專家十余名；在百余名員工中，專業(yè)人員占60%以上，博士、碩士二十余名。公司占地100畝，目前已建有一期一萬平方米的小核酸藥物研發(fā)生產(chǎn)基地，設(shè)有一流的研發(fā)生產(chǎn)設(shè)備。

　　百奧邁科發(fā)展至今，建立了小核酸文庫構(gòu)建、靶點(diǎn)高通量篩選、結(jié)構(gòu)修飾、規(guī)模化化學(xué)合成、藥物傳輸系統(tǒng)等技術(shù)于一體的完整藥物開發(fā)技術(shù)鏈。正在研發(fā)的多個抗腫瘤、抗病毒小核酸藥物取得突破性進(jìn)展。獲得國內(nèi)外發(fā)明專利40余項。2009年，百奧邁科投資成立了控股子公司“江蘇吉康生物技術(shù)有限公司”，推出世界首例小核酸美白祛斑產(chǎn)品，填補(bǔ)了國內(nèi)外空白，搶占了產(chǎn)業(yè)國際制高點(diǎn)。目前已經(jīng)形成以科研試劑和技術(shù)外包服務(wù)為短線產(chǎn)品、以小核酸美白祛斑系列產(chǎn)品為中線產(chǎn)品及以小核酸藥物研發(fā)、生產(chǎn)和銷售為長線產(chǎn)品的完整商務(wù)模式。

　　百奧邁科先后被評為國家博士后科研工作站、國家級高新技術(shù)企業(yè)、江蘇省工程技術(shù)研究中心等。2011年，百奧邁科成為“十二五”規(guī)劃全國唯一的小核酸重大新藥創(chuàng)制基地。另外，還承擔(dān)了多項國家、省、市級科技項目。

　　基于前沿的科研水平，百奧邁科建立了與國際知名藥企Benitec公司、Zetiq公司的科研合作。憑借良好的發(fā)展前景，百奧邁科正在凝聚更多力量，創(chuàng)新開拓，創(chuàng)業(yè)進(jìn)取，努力將企業(yè)打造成世界一流的核酸制藥集團(tuán)，為中國第三代新藥創(chuàng)制闖出一片新天地。

 Biomics Biotechnologies co. Ltd. is a pharmaceutical company in developing and commercializing RNAi based innovative products for disease treatments. The company was founded by Dr. York Zhu in 2006, registered with $ 12.12 M.

The company is managed by a professional team which is consisted with several oversea returnees. Over 60% of employees are with college degrees or above, including over 20 PhDs and Masters.

Biomics owns 16.6 acre land including 10000 m2 well-equipped R&D facility and possesses a comprehensive RNAi drug developing platforms comprised of Entire siRNA Targets Library, High-throughput Screening, Large-scale Synthesis, siRNA Delivery System and in-vivo Evaluation System. In addition, the company owns over 40 national and international patents.

Meanwhile, company possesses a pipeline with several ongoing programs for the treatments of Age-related Macular Degeneration (AMD), Hepatitis B, Bladder Cancer and other serious diseases. In 2009, first RNAi based product was launched by Genecon Biotech, a subsidiary of Biomics, for use of depigmentation. AMD candidate developed by Biomics scientists was successfully launched to pre-clinical stage which. It is not only an excellent validation of the company’s sophisticated technologies, but also a strong statement of the researchers' capabilities.

With the boost of Biomics in the last five years, in 2011, the company was selected as a national RNAi base. Additionally, Biomics has collaborative and partnership agreements with leading institutes worldwide, including Peking University, Benitec Biopharma (Australia) and Zetiq Technologies (Israel).